<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28776445</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1475-6374</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of enzyme inhibition and medicinal chemistry</Title><ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation></Journal><ArticleTitle>Inhibition of dengue virus replication by novel inhibitors of RNA-dependent RNA polymerase and protease activities.</ArticleTitle><Pagination><StartPage>1091</StartPage><EndPage>1101</EndPage><MedlinePgn>1091-1101</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2017.1355791</ELocationID><Abstract><AbstractText>Dengue virus (DENV) is the leading mosquito-transmitted viral infection in the world. With more than 390 million new infections annually, and up to 1 million clinical cases with severe disease manifestations, there continues to be a need to develop new antiviral agents against dengue infection. In addition, there is no approved anti-DENV agents for treating DENV-infected patients. In the present study, we identified new compounds with anti-DENV replication activity by targeting viral replication enzymes - NS5, RNA-dependent RNA polymerase (RdRp) and NS3 protease, using cell-based reporter assay. Subsequently, we performed an enzyme-based assay to clarify the action of these compounds against DENV RdRp or NS3 protease activity. Moreover, these compounds exhibited anti-DENV activity in vivo in the ICR-suckling DENV-infected mouse model. Combination drug treatment exhibited a synergistic inhibition of DENV replication. These results describe novel prototypical small anti-DENV molecules for further development through compound modification and provide potential antivirals for treating DENV infection and DENV-related diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pelliccia</LastName><ForeName>Sveva</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a Department of Drug Chemistry and Technologies , Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti , Roma , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yu-Hsuan</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>b Institute of Basic Medical Sciences , College of Medicine, National Cheng Kung University , Tainan , Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Center of Infectious Disease and Signaling Research , College of Medicine, National Cheng Kung University , Tainan , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coluccia</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Department of Drug Chemistry and Technologies , Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti , Roma , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Regina</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>a Department of Drug Chemistry and Technologies , Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti , Roma , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chin-Kai</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>b Institute of Basic Medical Sciences , College of Medicine, National Cheng Kung University , Tainan , Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Center of Infectious Disease and Signaling Research , College of Medicine, National Cheng Kung University , Tainan , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Famiglini</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>a Department of Drug Chemistry and Technologies , Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti , Roma , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masci</LastName><ForeName>Domiziana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>a Department of Drug Chemistry and Technologies , Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti , Roma , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiscott</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>d Istituto Pasteur Italia - Fondazione Cenci Bolognetti , Roma , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jin-Ching</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>e Department of Biotechnology, College of Life Science , Kaohsiung Medical University , Kaohsiung , Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>f Graduate Institute of Natural Products, College of Pharmacy , Kaohsiung Medical University , Kaohsiung , Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>g Research Center for Natural Products and Drug Development , Kaohsiung Medical University , Kaohsiung , Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>h Graduate Institute of Medicine , College of Medicine, Kaohsiung Medical University , Kaohsiung , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silvestri</LastName><ForeName>Romano</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>a Department of Drug Chemistry and Technologies , Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia - Fondazione Cenci Bolognetti , Roma , Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Enzyme Inhib Med Chem</MedlineTA><NlmUniqueID>101150203</NlmUniqueID><ISSNLinking>1475-6366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.48</RegistryNumber><NameOfSubstance UI="D012324">RNA-Dependent RNA Polymerase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C504449">NS3 protease, dengue virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012324" MajorTopicYN="N">RNA-Dependent RNA Polymerase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DENV inhibitors</Keyword><Keyword MajorTopicYN="N">ICR-suckling mouse</Keyword><Keyword MajorTopicYN="N">NS3 protease</Keyword><Keyword MajorTopicYN="N">RdRp</Keyword><Keyword MajorTopicYN="N">synergy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28776445</ArticleId><ArticleId IdType="pmc">PMC6010079</ArticleId><ArticleId IdType="doi">10.1080/14756366.2017.1355791</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rothman AL.Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011;11:532&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">21760609</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SH.Dengue virus-mosquito interactions. Annu Rev Entomol 2008;53:273&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17803458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ.. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep 2010;12:157&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">21308524</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche C, Cassar O, Laille M, Murgue B.. Dengue-3 virus genomic differences that correlate with in vitro phenotype on a human cell line but not with disease severity. Microbes Infect 2007;9:63&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17196421</ArticleId></ArticleIdList></Reference><Reference><Citation>Shurtleff AC, Beasley DW, Chen JJ, et al. . Genetic variation in the 3' non-coding region of dengue viruses. Virology 2001;281:75&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">11222098</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva RLA, de Silva AM, Harris E, MacDonald GH.. Genetic analysis of dengue 3 virus subtype III 5&#x2032; and 3&#x2032; non-coding regions. Virus Res 2008;135:320&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18436323</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilakis N, Weaver SC.. The history and evolution of human dengue emergence. Adv Virus Res 2008;72:1&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">19081488</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Mammen MP, Klungthong C, et al. . Comparative analysis reveals no consistent association between the secondary structure of the 3&#x2019;-untranslated region of dengue viruses and disease syndrome. J Gen Virol 2006;87:2595&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894198</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. . Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010;328:745&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, et al. . The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010;8:271&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Beltramello M, Messer WB, et al. . In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 2011;6:e1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119640</ArticleId><ArticleId IdType="pubmed">21713020</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, de Alwis AR, Kose N, et al. . Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol 2014;88:12233&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4248927</ArticleId><ArticleId IdType="pubmed">25100837</ArticleId></ArticleIdList></Reference><Reference><Citation>Yotmanee P, Rungrotmongkol T, Wichapong K, et al. . Binding specificity of polypeptide substrates in NS2B/NS3pro serine protease of dengue virus type 2: a molecular dynamics study. J Mol Graph Model 2015;60:24&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">26086900</ArticleId></ArticleIdList></Reference><Reference><Citation>Khromykh AA, Kenney MT, Westaway EG.. Trans-complementation of flavivirus RNA polymerase gene NS5 by using Kunjin virus replicon-expressing BHK cells. J Virol 1988;72:7270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109950</ArticleId><ArticleId IdType="pubmed">9696822</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlinson SM, Pryor MJ, Wright PJ, Jans DA.. Dengue virus RNA polymerase NS5: a potential therapeutic target? Curr Drug Targets 2006;7:1623&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17168837</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatem AJ, Hay SI, Rogers DJ.. Global traffic and disease vector dispersal. Proc Natl Acad Sci USA 2006;103:6242&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1435368</ArticleId><ArticleId IdType="pubmed">16606847</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Licensed Dengue vaccine: public health conundrum and scientific challenge. Am J Trop Med Hyg 2016;95:741&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062765</ArticleId><ArticleId IdType="pubmed">27352870</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy E, Lang J, Saville M, Jackson N.. Vaccination against Dengue: challenges and current developments. Ann Rev Med 2016;67:387&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">26515983</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble CG, Chen YG, Dong H, et al. . Strategies for development of dengue virus inhibitors. Antivir Res 2010;8:5450&#x2013;62.</Citation></Reference><Reference><Citation>Lim SP, Christian G, Noble CG, Shi PY.. The dengue virus NS5 protein as a target for drug discovery. Antiviral Res 2015;119:57&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">25912817</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinsona SM, Malmstroma RD, Russoa A, et al. . Structure-based discovery of dengue virus protease inhibitors. Antiviral Res 2009;82:110&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680748</ArticleId><ArticleId IdType="pubmed">19428601</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestri R, Cascio MG, La Regina G, et al. . Synthesis, cannabinoid receptor affinity and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. J Med Chem 2008;51:1560&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">18293908</ArticleId></ArticleIdList></Reference><Reference><Citation>La Pietra V, La Regina G, Coluccia A, et al. . Design, synthesis, and biological evaluatio of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3&#x3b2; inhibitors. J Med Chem 2013;56:10066&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">24295046</ArticleId></ArticleIdList></Reference><Reference><Citation>Manvar D, Pelliccia S, La Regina G, et al. . New 1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides inhibit hepatitis C virus replication via suppression of cyclooxygenase-2. Eur J Med Chem 2015;90:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">25483263</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MF, Alam MM, Verma G, et al. . The therapeutic voyage of pyrazole and its analogs: a review. Eur J Med Chem 2016;120:170&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">27191614</ArticleId></ArticleIdList></Reference><Reference><Citation>Corelli F, Massa S, Stefancich G, et al. . Agenti antiinfiammatori non steroidei. Nota V. - Sntesi di acidi 1-aril-5-(1-pirril)pirazolil-4-acetici a potenziale attivit&#xe0; antiinfiammatoria. Farmaco 1988;43:251&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">3417010</ArticleId></ArticleIdList></Reference><Reference><Citation>Erbel P, Schiering N, D'Arcy A, et al. . Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 2006;13:372&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">16532006</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259830</ArticleId></ArticleIdList></Reference><Reference><Citation>Korb O, Stutzle T, Exner TE, PLANTS: Application of ant colony optimization to structure-based drug design. In: Dorigo M, Gambardella LM, Birattari M, Martinoli A, Poli R, Stutzle T, eds. Ant colony optimization and swarm intelligence. Proceedings of the 5th International Workshop, ANTS, Lecture Notes in Computer Science, Series 4150, Berlin: Springer; 2006:47&#x2013;258.</Citation></Reference><Reference><Citation>Timiri AK, Sinha BN, Jayaprakash V. Progress and prospects on DENV protease inhibitors. Eur J Med Chem 2016;117:125&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">27092412</ArticleId></ArticleIdList></Reference><Reference><Citation>PyMOL, v1.8.6.0 , release March 9, 2017.  Available from: https://www.pymol.org.</Citation></Reference><Reference><Citation>Lin YT, Wu YH, Tseng CK, et al. . Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation. PLoS One 2013;8:e54466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554764</ArticleId><ArticleId IdType="pubmed">23365670</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JC, Tseng CK, Wu YH, et al. . Characterization of the activity of 2'-C-methylcytidine against dengue virus replication. Antiviral Res 2015;116:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25614455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu SF, Lin CK, Chuang YS, et al. . Anti-hepatitis C virus activity of 3-hydroxy caruilignan C from Swietenia macrophylla stems. J Viral Hepat 2012;19:364&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">22497816</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayani M, Filipe CDM, Ghosh R.. Cascade ultrafiltration systems integrated processes for purification and concentration of lysozyme. J Membrane Sci 2010;347:150&#x2013;8.</Citation></Reference><Reference><Citation>Hartwig S, Raschke S, Knebel B, et al. . Secretome profiling of primary human skeletal muscle cells. Biochim Biophys Acta 2014;1844:1011&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">23994228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao WW, Hong YH, Chen ML, Lin BF.. Inhibitory effects of Angelica sinensis ethyl acetate extract and major compounds on NF-&#x3ba;B trans-activation activity and LPS-induced inflammation. J Ethnopharmacol 2010;129:244&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20371279</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu G, Lou Z, Gupta M.. The long non-coding RNA GAS5 cooperates with the eukaryotic translation initiation factor 4E to regulate c-Myc translation. PLoS One 2014;9:e107016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4157848</ArticleId><ArticleId IdType="pubmed">25197831</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng CK, Lin CK, Wu YH, et al. . Human heme oxygenase 1 is a potential host cell factor against dengue virus replication. Sci Rep 2016;6:32176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4995454</ArticleId><ArticleId IdType="pubmed">27553177</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannous BA.Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc 2009;4:582&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692611</ArticleId><ArticleId IdType="pubmed">19373229</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SM, Watowich SJ.. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease. Antiviral Res 2011;89:127&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026091</ArticleId><ArticleId IdType="pubmed">21185332</ArticleId></ArticleIdList></Reference><Reference><Citation>7-Amino-4-methylcoumarin (AMC) fluorophore-linked peptide substrate Boc-GRR-AMC. Bachem, CA, USA; 2016. Available from: http://www.bachem.com/ [last accessed 29 Nov 2016].</Citation></Reference><Reference><Citation>Yildiz M, Ghosh S, Bell AJ, et al. . Allosteric inhibition of the NS2B-NS3 protease from dengue virus. ACS Chem Biol 2013;8:2744&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923078</ArticleId><ArticleId IdType="pubmed">24164286</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhametov A, Newhouse EI, Ab Aziz N, et al. . Allosteric pocket of the dengue virus (serotype 2) NS2B/NS3 protease: in-silico ligand screening and molecular dynamics studies of inhibitors. J Mol Graph Model 2014;52:103&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">25023665</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandramouli S, Joseph JS, Daudenarde S, et al. . Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J Virol 2010;84:3059&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826037</ArticleId><ArticleId IdType="pubmed">20042502</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein data bank. Available from: http://www.rcsb.org/pdb/home/home.do [last accessed 6 Dec 2016].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>